Buján Murlà, Núria (Date of defense: 2016-01-29)
The diagnose of a mitochondrial disease implies biochemical studies such as the enzymatic activities of the mitochondrial respiratory chain (MRC) and the quantification of the amount of CoQ10 in energetic ...
Oliveras Ferrarós, Cristina (Date of defense: 2013-06-21)
The aim of this doctoral thesis was to unravel mechanisms underlying primary resistance to trastuzumab regarding a putative new breast cancer subtype with mixed basal & ErbB2+ molecular features. Using ...
Carrion-Salip, Dolors (Date of defense: 2014-09-17)
Most current chemotherapeutic agents are of limited use due to their side effects and the resistance to treatment that tumour cells develop. In this thesis, we have contributed to the knowledge of these ...
Cufí González, Sílvia (Date of defense: 2015-05-22)
Aquest és el primer informe que demostra que l'autofàgia està mecànicament vinculat al manteniment de les cèl•lules tumorals que expressen alts nivells de CD44 i baixos nivells de CD24, que són típics ...
González Bártulos, Marta (Date of defense: 2017-03-17)
Nowadays, cancer is one of the leading causes of death in developed countries. Therefore, there is great interest of developing new therapeutic strategies to improve the efficiency of current cancer ...
Soler Campmajó, David (Date of defense: 2014-10-30)
Les inteïnes són dominis proteics que mitjançant un procés de tall i unió s’autoescindeixen de la cadena polipeptídica precursora i catalitzen la unió de les seqüències flanquejants (exteïnes) mitjançant ...
Tubert Juhé, Pere (Date of defense: 2012-07-24)
Ribonucleases are promising candidates for use in anticancer therapy. There are different ways to endow an RNase with antitumor properties. Targeting the enzyme to the cell nucleus is a potential approach. ...
García Galindo, Glòria (Date of defense: 2016-07-19)
Les ribonucleases són enzims que presenten citotoxicitat selectiva per a cèl·lules tumorals. S'ha proposat l’ús de ribonucleases dirigides a nucli (ND-RNases) com a fàrmacs antitumorals. En aquest treball ...
Comajoan von Arend, Pau (Date of defense: 2019-12-18)
Recombinant tissue plasminogen activator (rt-PA) is currently the only FDA-approved drug for the treatment of acute ischaemic stroke. However, the application of this therapy is limited to <5-7% of ...